anti-claudin 18.2 CAR T-cell therapy (ICON clinical research)

N/A

Report date: 2025/03/14 16:51:39

Base Information

Drug Nameanti-claudin 18.2 CAR T-cell therapy (ICON clinical research)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionClaudin 18 protein modulators

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsStomach Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIreland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesIcon Clinical Research Ltd

China Registration ClassN/A

Develop Information

Active CompaniesIcon Clinical Research Ltd

Inactive CompaniesN/A

Active IndicationsStomach Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A